跳至主要内容
临床试验/NCT04654325
NCT04654325终止不适用

Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients

Assistance Publique - Hôpitaux de Paris2 个研究点 分布在 1 个国家目标入组 534 人开始时间: 2021年1月19日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
534
试验地点
2
主要终点
presence of SARS-CoV-2 genome in tears

研究概览

简要总结

To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.

详细描述

Patients attending to the COVID19 screening facility of Paris South University hospital and willing to participate to the study will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. The project will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a standardized questionnaire.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual care
  • Information and signature of consent
  • Affiliated with a social security scheme or entitled

排除标准

  • Refusal to participate in the study
  • Eye surgery less than 3 months old
  • Unable to give informed consent
  • No coverage through the health insurance system
  • Patient under judicial protection
  • Patient on AME

结局指标

主要结局

presence of SARS-CoV-2 genome in tears

时间窗: at the end of the study, an average of 1 year

Prevalence of SARS-CoV-2 genome in tears

次要结局

  • presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation(at the end of the study, an average of 1 year)
  • assessement of viral load levels(at the end of the study, an average of 1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Prevalence of SARS-CoV-2 Genome in Tears of... | 临床试验